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months following unblinding showed a decrease of BP in the RDN
arms over time and an increase in BP in the control/non-crossover arm
from 6 to 12 months as assessed by both ofﬁce and ambulatory BP
(Figure). Outcomes at 24 months, including ofﬁce and ambulatory BP,
available at TCT 2015, will be important to assess whether this pattern
is maintained. Long-term safety will also be presented.
CONCLUSIONS The ofﬁce systolic BP reduction in the RDN arm
continued to increase between 6 and 12 months while the opposite
relationship existed in the non-crossover patients. Outcomes at
24 months of unblinded treated subjects and non-treated control
subjects will provide new insights to guide our continued under-
standing of the effects of patient selection, medication burden, and
medication adherence in patients with treatment-resistant hyperten-
sion as well as conﬁrm long-term safety in this large population
treated with RDN.
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BACKGROUND Posthoc analysis of SYMPLICITY HTN-3 has revealed a
trend for greater blood pressure reductions with increasing number of
ablations and highlighted the difﬁculty of achieving uniform and
circumferential ablation pattern using single electrode renal dener-
vation catheters. We examined whether iterative low power multi-
electrode bipolar-unipolar treatments based on local closed-loop
temperature sensing can provide effective four quadrant ablations.
METHODS Ten porcine renal arteries were treated once (n¼4) proxi-
mally or twice in sequence (n¼6) w6mm distal to the aortic ostium of
the renal artery using the ReDy system with a 72C set point (1.10.5
W, n¼10). A low proﬁle, 9-electrode, over-the-wire, RF ‘basket’ catheter
with closed loop temperature control, and a smart generator delivers
a 60sec sequence of bipolar and unipolar treatments designed to
ensure that each electrode meets a temperature-duration objective.
Catheters were advanced into the renal artery and positioned for
treatment using a 6-Fr guiding sheath under ﬂuoroscopic guidance.
In the dual treatment group the catheter was retracted half a basket
length after the ﬁrst treatment. At 7 days post treatment, kidneys
were harvested for norepinephrine (NEPI) quantiﬁcation and arteries
processed for histopathology. Post treatment NEPI levels were evalu-
ated relative to our published baseline levels (666222 ng/g, n¼12)
to calculate percent reductions. Automated image processing of H&Estained tissue sections estimated the percentage of affected circum-
ference up to a depth of 5 mm from the lumen.
RESULTS There was no angiographic evidence of acute dissection,
perforation, or occlusion at the time of the procedure or subsequently.
Histologically all treated arterial sections exhibited advanced re-
endothelialization, with progressive arterial and peri-arterial repair,
and no evidence of adverse effects on arteries or surrounding tissue.
Summation of ablation effects over multiple tissue sections revealed
that a larger percentage of the total circumferential arc was affected
by dual treatments compared to single treatments up to 3 mm from
the lumen. The difference between single and dual treatments was
particularly pronounced up to 1 mm away from the lumen, 53.531.6%
vs 87.511.2% (p¼0.11) and appeared to predict relative NEPI reduc-
tion, 60.638.5% (p¼0.03) vs 88.117.0% drop (p<0.001).
CONCLUSIONS We and others have argued for distal treatments
based on the relative accessibility of target nerves, yet such treat-
ments carry greater risk of affecting surrounding organs, particularly
close to the hilus. The data herein illustrate that low power dual distal
treatments using the Renal Dynamics ReDy system provide effective
circumferential ablation without affecting arterial patency or sur-
rounding organs.
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BACKGROUND Percutaneous sympathetic renal artery denervation is
available for the treatment of patients with resistant hypertension.
We further investigated the safety and efﬁcacy of a multi-electrode
renal denervation system (EnligHTN) in patients with severe un-
controlled hypertension.
METHODS The EnligHTN-II study is a post-market clinical investiga-
tion in which patients were assigned to one of three groups; Group A,
ofﬁce systolic BP (OSBP) 160 mmHg and estimated glomerular
ﬁltration rate (eGFR) 45 mL/min per 1.73 m2, Group B, OSBP 140-
159 mmHg and eGFR 45 mL/min per 1.73 m2 and Group C,
OSBP 140 mmHg and eGFR 15 mL/min per 1.73 m2. For all three
groups subjects were required to be on at least 3 anti-hypertensive
medications (including 1 diuretic), or to have documented drug
intolerance such that they are unable to take 3 anti-hypertensive
drugs. Responder analysis was also performed using a 5mmHg
reduction in ambulatory systolic measurement to deﬁne responders.
RESULTS 133 patients from Group A (average age 61.6  9.5 yrs taking
on average 4.3 2.3 anti-hypertensive medications) were included.
Bilateral renal nerve ablation was performed using a percutaneous
femoral approach. Baseline average OSBP was 181.9  16 mmHg,
average ofﬁce diastolic BP (ODBP) was 97.8  15.9 mmHg, average
24hr ambulatory SBP (ASBP) was 159.4  17 mmHg, and average 24hr
ambulatory DBP (ADBP) was 88.7  12.9 mmHg. At present, 119 6-
month and 88 12-month follow-up visits are completed. The average
reduction in OSBP/ODBP was 18.5/8.4 mmHg and 18.2/9.5 mmHg at 6-
and 12-month follow up respectively (p<0.0001 for all). The average
reduction in ASBP/ADBP was 7.1 /3.8 mmHg (p<0.0001 for both) and
9.8 /4.2 mmHg (p<0.001 for both) at 6 and 12M follow up respectively.
Neither eGFR nor serum creatinine changed signiﬁcantly from base-
line at either 6 or 12-months follow up. The following baseline factors
were associated with the responder group at the 90% conﬁdence
level: younger age, less sleep apnea, higher eGFR, lower serum
creatinine, higher systolic & diastolic ambulatory pressures.
CONCLUSIONS In this real world, post-marketing study we demon-
strate that multi-electrode renal denervation results in durable, highly
signiﬁcant and safe lowering of both ofﬁce BP and ambulatory BP
parameters in patients with severe uncontrolled hypertension up to 12
months following treatment.
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BACKGROUND Catheter-based renal artery denervation therapy has
become established as a therapeutic option in patients with resistant
hypertension. We further investigated the safety and performance of
the next generation EnligHTN Renal Denervation System (St. Jude
Medical) in patients with drug-resistant hypertension.
METHODS The EnligHTN Renal Artery Ablation Catheter has 4
electrodes attached on a basket mounted at the tip of the catheter.
The basket is collapsed and can be expanded via an external mecha-
nism once the catheter is placed in the desired location of the renal
artery. The next generation EnligHTN RF Ablation Generator
utilizes a novel algorithm for the delivery of 1 minute of radio-
frequency energy, optimized for simultaneous delivery of therapy
through all 4 electrodes, with an interactive, intuitive user interface.
Renal denervation was performed on 39 patients across 6 centers
meeting the following inclusion criteria: 18-80 years of age, a
systolic BP 160 mmHg, an average daytime systolic ambulatory
BP 135 mmHg, on three or more antihypertensive agents (including a
diuretic), and renal artery diameter 4mm and length 20mm. The
primary endpoints are 1) to characterize the rate of serious procedural
and device related adverse events from date of procedure through 6
months post procedure and 2) the change in ofﬁce BP at 6 months post
procedure. The secondary endpoints include the changes in 24 hour
ambulatory BP and the characterization of renovascular safety and
renal function change over time from baseline. Renal artery CT angi-
ography was repeated at 6 months in all patients. The multi-electrode
ablation catheter was introduced into each renal artery and two sets of
denervation therapy delivered per renal artery.
RESULTS To date 37/38 patients have completed 18-months of follow-
up post procedure. One serious device or procedure related adverse
event, a pseudo aneurysm, has been observed as adjudicated by an
independent Clinical Events Committee. There were no clinically
signiﬁcant changes in renal function through 18-months as observed
in eGFR, serum creatinine, cystatin C, or urine albumin-to-creatinine
ratio. 18-month ofﬁce (and 12M, 24 hour ambulatory) BP reductions
from baseline were -25/-8 (-11/-4) mmHg, which were statistically
signiﬁcant except for the ambulatory diastolic reduction. Renal artery
denervation procedures were performed successfully in all patients,
with an average of 4.33 ablation sets and 15.85 ablations performed
per patient. The mean total ablation catheter insertion-to-removal
time was 22.38 min and mean ablation time was 4.33 min per patient.
CONCLUSIONS Accumulated 24-month results from all sites will be
presented at the meeting. After 18-months follow-up post procedure
in this ﬁrst-in-human study, we conclude that data demonstrates the
next generation EnligHTN Renal Denervation System continues to be
safe, rapid, and effective in the treatment of patients with drug-
resistant, uncontrolled hypertension.
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BACKGROUND The Kona Medical Surround Sound System is a non-
invasive device for renal denervation that delivers externally focused
ultrasound to the renal nerves using Doppler-based image guidance to
track and correct for renal artery motion during the procedure. Aims:
To evaluate the safety and efﬁcacy of an entirely non-invasive
approach to renal denervation using externally delivered focused ul-
trasound with real time Doppler-based image guidance in treatment
resistant hypertension (TRH).
METHODS In 3 consecutive studies 69 patients with severe TRH,
deﬁned as persistent systolic blood pressure (BP) > 160 mmHg
despite 3 or more antihypertensive medications, were treated non-
invasively with the Kona Medical Surround Sound System. Focused
ultrasound energy was delivered to the renal arteries bilaterally and
surrounding tissue using Doppler-based imaging and continuous
tracking with automatic correction for kidney motion throughout
treatment. Patients received conscious sedation during the treatment
period.
RESULTS At this time, all patients have completed 24 weeks
follow-up and 61 patients have completed 52 weeks of follow-up.
Post-denervation, the mean changes from baseline BP were -16.2/-
6.7 mmHg at 3 weeks, -22.3/-9.0 mmHg at 6 weeks, -24,4/-9.9 mmHg
at 12 weeks, -24.6/-9.0 mmHg at 24 weeks and -22.9/-9.9 mmHg 52
weeks . Response rates (drop in BP by > 10 mmHg) was 75% at 6
and 12 months. No serious intervention related events have been
reported to date. Forty-six percent of subjects (32/69) reported mild
back pain immediately following the denervation treatment. The
majority of cases (19/32) completely resolved within seven days post
treatment and no case was associated with any motor, sensory
deﬁcits.
CONCLUSIONS This is the ﬁrst data in humans using a non-invasive
renal denervation system in severe TRH. Results showed clinically
meaningful reductions in ofﬁce BP through 52 weeks post-denerva-
tion. The procedure was well-tolerated with no serious adverse
events. Sham-operator controlled studies with the Kona systems to
evaluate the safety and efﬁcacy of this novel non-invasive treatment
are in the recruiting and planning stages.
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BACKGROUND Despite recent setbacks and limitations with radio-
frequency (RF)-based therapies, there is continued interest in
renal denervation as a therapy for uncontrolled hypertension. We
present an update of targeted “chemical renal denervation” using
alcohol as the neurolytic agent, as an alternative method for renal
denervation.
METHODS The Peregrine System is a novel endovascular catheter
with three micro-needles which are deployed into the perivascular
